Concepedia

A novel, potent, and orally active VLA-4 antagonist with good aqueous solubility: trans-4-[1-[[2-(5-Fluoro-2-methylphenylamino)-7-fluoro-6-benzoxazolyl]acetyl]-(5S)-[methoxy(methyl)amino]methyl-(2S)-pyrrolidinylmethoxy]cyclohexanecarboxylic acid

Masaki Setoguchi, Shin Iimura, Yuuichi Sugimoto, Yoshiyuki Yoneda, Jun Chiba, Toshiyuki Watanabe, Fumihito Muro, Yutaka Iigo, Gensuke Takayama, Mika Yokoyama,

Bioorganic & Medicinal Chemistry · 2012 · 23 citations · 22 references

DOIFull text

Open access

Concepts

References

22

VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/Fibronectin binding site

Mariano J. Elices, Laurelee Osborn, Yoshikazu Takada et al. · Cell · 1990 · 1.8K citations

, , +17

Prevention of experimental autoimmune encephalomyelitis by antibodies against α4βl integrin

Ted Yednock, Catherine Cannon, Lawrence C. Fritz et al. · Nature · 1992 · 1.7K citations

, , +12

A Controlled Trial of Natalizumab for Relapsing Multiple Sclerosis

David H. Miller, Omar Khan, William Sheremata et al. · New England Journal of Medicine · 2003 · 1.2K citations · Full text

, , +16

Natalizumab for Active Crohn's Disease

Subrata Ghosh, Eran Goldin, F. Gordon et al. · New England Journal of Medicine · 2003 · 815 citations

, , +16

Identification and characterization of the T lymphocyte adhesion receptor for an alternative cell attachment domain (CS-1) in plasma fibronectin.

Elizabeth A. Wayner, Angeles Garcı́a-Pardo, Martin J. Humphries et al. · The Journal of Cell Biology · 1989 · 794 citations · Full text

, , +16